Adiumentum intends to engage in conversations, meetings and other communications with certain members of the Atara’s board of directors and management team, stockholders, industry analysts, and other interested parties, in each case to discuss its business, operations, financial condition, strategic plans and governance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics submits BLA to FDA for tabelecleucel
- Atara Biotherapeutics reports Q1 EPS (23c), consensus (26c)
- Atara Biotherapeutics price target lowered to $2.30 from $4.80 at Stifel
- Atara Biotherapeutics Board Member Decides Not to Seek Re-Election
- Atara Biotherapeutics’ Profitability Hinges on Partners’ Success with Ebvallo Amid Market Challenges